scholarly journals Prognostic value of endoglin-assessed microvessel density in cancer patients: a systematic review and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 9 (7) ◽  
pp. 7660-7671 ◽  
Author(s):  
Jinguo Zhang ◽  
Lingyun Zhang ◽  
Qunbo Lin ◽  
Weimin Ren ◽  
Guoxiong Xu
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Microvessel Density ◽  
Prognostic Value ◽  
Meta Analysis

scholarly journals Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: a systematic review and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (66) ◽  
pp. 110606-110613 ◽  
Author(s):  
Wen Li ◽  
Guangzhi Ma ◽  
Qiang Wu ◽  
Yunfu Deng ◽  
Ya Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Lung Cancer Patients ◽  
Lymphocyte To Monocyte Ratio

scholarly journals The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis

PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0182562 ◽  
Author(s):  
Rongyuan Zhuang ◽  
Song Li ◽  
Qian Li ◽  
Xi Guo ◽  
Feng Shen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Kras Mutation ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Yao Jin ◽  
Aili Tan ◽  
Jia Feng ◽  
Zexi Xu ◽  
Peiwei Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
T Cells ◽  
Cancer Patients ◽  
Cd8 T Cells ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Prognostic Impact ◽  
Free Survival ◽  
Memory Cd8 T Cells

ObjectiveThe objective of this systematic review and meta-analysis was to determine the prognostic value of memory CD8(+) T cells in cancer patients with immunotherapy.MethodsEMBASE, MEDLINE (PubMed), and Web of Science databases were searched to identify suitabile articles published before March 2021. Risk of bias on the study level was assessed using the Cochrane Bias Risk Assessment Tool. The hazard ratios (HRs) and 95% confidence intervals (CIs) of pooled progression-free survival (PFS) and overall survival (OS) were calculated using RevMan 5.4 to evaluate the prognostic impact of memory CD8(+) T cells.ResultsIn total, nine studies were included in the final analysis. High levels of memory CD8(+) T cells were significantly closely correlated with better progression-free survival (PFS) and overall survival (OS) of cancer patients with immunotherapy (PFS, HR 0.64, 95% CI 0.53–0.78; OS, HR 0.37, 95% CI 0.21–0.65). Memory CD8(+) T cells still have significant prognostic value in cancer patients given immunotherapy alone after excluding of other interfering factors such as chemotherapy, radiotherapy, and targeted therapy (PFS, HR 0.65, 95% CI 0.48–0.89; OS, HR 0.23, 95% CI 0.13–0.42). However, high memory CD8(+) T cells levels did not correspond to a longer PFS or OS in cancer patients with non-immunotherapy (PFS, HR 1.05, 95% CI 0.63–1.73; OS, HR 1.29, 95% CI 0.48–3.48). Thus, memory CD8(+) T cells might be a promising predictor in cancer patients with immunotherapy.ConclusionsThe host’s overall immune status, and not only the tumor itself, should be considered to predict the efficacy of immunotherapy in cancer patients. This study is the first to show the significant prognostic value of memory CD8(+) T cells in immunotherapy of cancer patients through systematic review and meta-analysis. Thus, the detection of memory CD8(+) T cells has a considerable value in clinical practice in cancer patients with immunotherapy. Memory CD8(+) T cells may be promising immunotherapy targets.

Sign in / Sign up

Export Citation Format

Share Document